Akriderm, 0.05% ointment 30 g

Pharmgroup:

Glucocorticosteroid for topical use.

Pharm Action:

The corticosteroid betamethasone dipropionate has anti-inflammatory, anti-allergic, anti-exudative, anti-edema and antipruritic effects.

Inhibits leukocyte accumulation, release of lysosomal enzymes and anti-inflammatory mediators in the inflammation focus, inhibits phagocytosis, reduces vascular and tissue permeability and prevents formation of inflammatory edema.

Indications

Allergic skin diseases (including acute, subacute and chronic contact dermatitis, occupational dermatitis, seborrheic dermatitis, atopic dermatitis, solar dermatitis, neurodermatitis, pruritus, dyshidrotic dermatitis, eczema);
acute and chronic forms of non-allergic dermatitis;
psoriasis.

Pharmacological effect

Pharmaceutical group:

glucocorticosteroid for local use.

Pharmaceutical action:

The corticosteroid betamethasone dipropionate has anti-inflammatory, antiallergic, antiexudative, decongestant and antipruritic effects.

Inhibits the accumulation of leukocytes, the release of lysosomal enzymes and anti-inflammatory mediators at the site of inflammation, inhibits phagocytosis, reduces vascular tissue permeability, and prevents the formation of inflammatory edema.

Special instructions

If signs of hypersensitivity or skin irritation associated with the use of the drug are observed, treatment should be discontinued and adequate therapy should be selected for the patient. With prolonged treatment, when applying the drug to large surfaces of the skin, when using occlusive dressings, and also in children, systemic absorption of glucocorticosteroids is possible.

For children over 1 year of age, the drug is prescribed only according to strict indications and under medical supervision, since the development of systemic side effects associated with betamethasone is possible.

When using the drug on large surfaces and/or under an occlusive dressing, suppression of the function of the hypothalamic-pituitary-adrenal system and the development of symptoms of hypercortisolism may occur; a decrease in the excretion of growth hormone and an increase in intracranial pressure may be observed.

Atrophic changes may appear on the skin of the face more often than on other surfaces of the body after long-term treatment with topical glucocorticosteroids; the course of treatment in this case should not exceed 5 days.

Akriderm® cream is not intended for use in ophthalmology. Avoid getting the drug in your eyes.
With long-term use of the drug, its withdrawal should be carried out gradually.

Active ingredient

Betamethasone

Composition

1 g:

– betamethasone dipropionate 0.64 mg;

excipients:

propyl parahydroxybenzoate,

Vaseline oil,

isopropyl myristate,

petrolatum.

Contraindications

Hypersensitivity to any of the components of the drug, bacterial, fungal skin diseases, skin tuberculosis, skin manifestations of syphilis, chicken pox, herpes simplex, skin post-vaccination reactions, open wounds, trophic leg ulcers, rosacea, acne vulgaris, skin cancer, nevus, atheroma, melanoma, hemangioma, xanthoma, sarcoma, lactation period and children under 1 year of age.

With caution

Pregnancy.

With long-term use or applied to large surfaces: cataracts, diabetes, glaucoma, tuberculosis.

Side Effects

With local use of glucocorticosteroids, the following may be observed: burning, irritation, dry skin, folliculitis, hypertrichosis, acne-like rashes, itching, stretch marks, miliaria, hypopigmentation, perioral dermatitis.

With long-term use, as well as the use of occlusive dressings, skin maceration, secondary infection, skin atrophy, prickly heat, purpura, local hirsutism, telangiectasia.

When applied to large surfaces of the body, mainly in children, systemic side effects of glucocorticosteroids may occur (gastritis, ulceration of the gastrointestinal mucosa, hyperglycemia, glycosuria, reversible inhibition of adrenal function, manifestation of Cushing’s syndrome).

If adverse reactions occur that are not described in the instructions, you should consult a doctor.

Interaction

No interactions of the drug Akriderm with other drugs have been identified.

Overdose

Acute overdose is unlikely, however, with excessive or prolonged use of the drug, chronic overdose is possible, accompanied by signs of hypercortisolism: hyperglycemia, glycosuria, reversible inhibition of adrenal function, manifestation of Cushing’s syndrome.

Treatment. Appropriate symptomatic treatment is indicated. In case of chronic toxic effects, gradual withdrawal of the drug is recommended.

Recommendations for use

The safety of topical use of glucocorticosteroids in pregnant women has not been established; the prescription of drugs in this group during pregnancy is justified only if the potential benefit to the mother outweighs the possible risk to the fetus. During pregnancy, drugs in this group should not be used in high doses or for long periods of time.

If it is necessary to use the drug during lactation, it is recommended to stop breastfeeding.

Storage conditions

The drug should be stored out of the reach of children at a temperature of 15 to 25°C.

Shelf life

2 years.

Manufacturer

Akrikhin JSC, Russia